The center integrates the work of faculty, trainees and staff. Gene Morse is the center director and works closely with a scientific leadership committee and an advisory board.
Gene Morse also directs the Translational Pharmacology Research Core in UB's New York State Center of Excellence in Bioinformatics and Life Sciences. He has been actively involved in drug development research since the introduction of antiretrovirals for HIV in 1986, with more recent emphasis on HCV infection and antiviral drug development.
He is the principal Investigator for the NIH Fogarty International Center, HIV Research Training Program with the University of Zimbabwe, co-chair of the SUNY-University of the West Indies Faculty Task Force for Health Research Development and chair of the Buffalo Jamaica Innovation Enterprise Executive Committee. Morse is the hub steward for the Western New York Science, Technology, Engineering and Mathematics (STEM) Hub.
Terrence Forrester holds fellowships in the Royal College of Physicians of both London and Edinburgh and is a professor of experimental medicine at the University of the West Indies Mona Campus.
His research focuses on risks and impacts of obesity, metabolic programming of early life and the constraints of fetal growth, and understanding the economic implications of chronic diseases and their intervention. He spearheaded the formation of the Tropical Medical Research Institute, which unified four research units—the Tropical Metabolic Research Unit, the Sickle Cell Research Unit, the Epidemiology Research Unit at Mona, Jamaica, and the Chronic Disease Research Unit in Barbados—across three campuses of the University of the West Indies.
James Hakim is a professor of medicine at the University of Zimbabwe in the College of Health Sciences, and is a cardiologist with more than 20 years of experience conducting clinical trials. He is the leader of the University of Zimbabwe Parirenyatwa Clinical Research Site and is an active member of the NIH AIDS Clinical Trials Group network. Professor Hakim has served as a member of the Scientific Agenda Steering Committee, Antiretroviral Committee and HPTN Executive Committee.
John Lindo also is a consultant parasitologist to the University Hospital of West Indies. Professor Lindo is co-chair of the SUNY-University of the West Indies Faculty Task Force for Health Research Development. His research has focused on the epidemiology of soil-transmitted helminths and emerging infectious diseases. This includes the epidemiology of strongyloides stercoralis infections and toxocariasis, the emergence of malaria and angiostrongylus cantonensis infections in Jamaica, epidemiology of free-living amoebae in Jamaica and opportunistic parasitic infections in persons living with HIV/AIDS.
Charles Chiedza Maponga also holds a visiting faculty position with the UB School of Pharmacy and Pharmaceutical Sciences. He travels frequently between UB and the University of Zimbabwe while coordinating the activities of an international collaborative program, the International Pharmacotherapy Education and Research Initiative. Professor Maponga is the University of Zimbabwe's principal investigator for the NIH Fogarty International Center HIV Research Training program. He works to implement a postgraduate and postdoctoral training initiative between the two universities with an emphasis on HIV clinical pharmacology.
Craig Hendrix is currently the Wellcome Professor and Director, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine. He trained in infectious diseases and clinical pharmacology at Hopkins before a career in the US Air Force and at Johns Hopkins.
Dr. Hendrix’s primary research focus is clinical pharmacology of HIV pre-exposure prophylaxis. Among other research projects, he’s involved as Principal Investigator or Project Leader in a variety of early phase PrEP program project grants funded through the DAIDS Integrated Clinical/Preclinical HIV Topical Microbicide Program. He also serves as director of the pharmacology group for the MTN and HPTN.
Timothy Murphy is a SUNY distinguished professor and senior associate dean for Clinical and Translational Research in UB's Jacobs School of Medicine and Biomedical Sciences. He oversees strategies to transform UB’s research programs into new or improved treatments for patients as well as assisting faculty and trainees at all levels with their research activities. He directs the school's Clinical and Translational Research Center, located on the Buffalo Niagara Medical Campus that includes a nine-bed clinical research center with support services for clinical research. He focuses on infectious diseases.
Paras Prasad also holds the Samuel P. Capen Chair at UB and is the executive director of the multidisciplinary Institute for Lasers, Photonics and Biophotonics. He has published more than 700 scientific papers, co-edited six books and co-authored a monograph (with D.J. Williams) "Introduction to Nonlinear Optical Effects in Molecules and Polymers." Professor Prasad published "Introduction to Biophotonics," the first monograph in this field, which authoritatively defines the field, details its scope and identifies emerging opportunities. He also has published the monograph, "Nanophotonics" and "Introduction to Nanomedicine and Nanobioengineering."
Stanley Schwartz is working to develop unique therapies for treatment of metastatic prostate cancer and chronic viral infections involving the brain. The processes include nanotechnology, as well as allergy and immunology, proteins, metalloenzymes and RNA.
Andrew Talal conducts clinical and translational research in viral hepatitis. He studies viral decay and the concentrations of drugs in the liver. He directs the Center for Clinical Care and Research in Liver Disease at UB’s Clinical and Translational Research Center. His lab has received multi-year funding for its research programs. It has developed techniques for animal and human liver sampling that enable sorting of liver cells in order to understand drug distribution in the liver during treatment.
James Mohler earned his medical degree from the Medical College of Georgia and completed residency training in Surgery and Urology at the University of Kentucky Medical Center and a research fellowship in Urologic Oncology at The Johns Hopkins University School of Medicine. Dr. Mohler is licensed by New York and North Carolina, a Diplomate of the National Board of Medical Examiners and the American Board of Urology, and a Fellow of the American College of Surgeons. He was Chair of the Roswell Park Department of Urology for 14 years. Dr. Mohler is Chair of the National Comprehensive Cancer Network (NCCN) Guidelines Panel for Prostate Cancer and Past-President of the Society for Basic Urologic Research (SBUR). He has received the Producers Award and the Rodger J. Winn Award from NCCN and a career achievement award from SBUR.
Dr. Anton graduated magna cum laude from Harvard University in 1977 and received his MD from Case Western Reserve University in 1983. He did fellowship work at the Cholera Hospital, ICDDR, in Bangladesh in 1983 and a year fellowship in pathology in 1981 in Cleveland’s Institute of Pathology. He performed his internship and residency in internal medicine at Bringham and Women’s Hospital in Boston Massachusetts. Dr. Anton began in his work at UCLA in 1986 with a gastroenterology fellowship and has been on faculty since 1989.
Dr. Anton’s research focuses on the degree of mucosal inflammation and altered co-receptor expression associated with HIV infection and associated therapeutic interventions, the potential use of the mucosa as a route of HIV immunization with various HIV vaccine candidates as well as microbicides for HIV mucosal prevention, investigating the interaction of HSV and HIV in mucosal pathogenesis and efforts to clarify the role of compartments in HIV pathogenesis.
Robert Genco leads the UB Microbiome Center which is enhancing studies of the human microbiome—the community of organisms that share our body space—to better understand its role in health and disease.
A world-renowned scientist with demonstrated success in commercializing both his own discoveries and those of others, Genco's research focuses on the mechanisms of virulence of mucosal pathogens. Adherence is a critical first step in the pathogenesis of mucosal diseases, as it is important in interactions with mammalian cells, which can activate macrophages and play a role in invasion of epithelial cells.
ON THIS PAGE:
Lauren Barredo, Head of Partnerships Sustainable Development Solutions Network
Robin DiFrancesco, Scientific Manager, CIGBS, University at Buffalo
Karl Donn, Vice President, Drug Development Parion Sciences
Ative Ennis, Head of Innovation and Enterprise Solutions, Digicel
Matt Enstice, Chief Executive Officer, Buffalo Niagara Medical Campus
Garthfield Gibson, Comptroller, Spectrum Radiology Associates
John Hatcher, Vice President of Business Development, Accessium Group
Gabriella Heffesse, Chief Operating Officer, ACG Anyalytics
John Lindo, PhD, Deputy Dean for Research, University of the West Indies, Mona Campus
Charles Chiedza Maponga, PharmD, MPHE Senior Lecturer and Director, School of Pharmacy, University of Zimbabwe College of Health Sciences
Beverly Joy Morrison, President and CEO, Mount Regale Practice Management
William Pearce, Managing Partner, PEARCECO VENTURES, LLC
Trevor Poag, PhD, Director of Global Learning Opportunities, University at Buffalo
Satish Sharma, Charman and Chief Executive Officer, You First Services
Patrick Sheehan, Co-Founder and Executive Director, Peter Sheehan Diabetes Care Foundation
Dorothy Siaw-Asamoah, Faculty Director of Global Programs, University at Buffalo
Sue Siminiski, CEO, Frontier Science
Paul Tesluk, Dean and Professor of the School of Management, University at Buffalo